Cas:168759-60-2 7-Bromo-4H-chromen-4-one manufacturer & supplier

We serve Chemical Name:7-Bromo-4H-chromen-4-one CAS:168759-60-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

7-Bromo-4H-chromen-4-one

Chemical Name:7-Bromo-4H-chromen-4-one
CAS.NO:168759-60-2
Synonyms:7-Bromochromone;7-bromochromen-4-one
Molecular Formula:C9H5BrO2
Molecular Weight:225.03900
HS Code:2914700090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:30.21000
Exact Mass:223.94700
LogP:2.55550

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 7-Bromochromone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-bromochromen-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Bromochromone Use and application,7-Bromochromone technical grade,usp/ep/jp grade.


Related News: In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis. 2,2′-Dimethoxy-4′-nitro-5,5′-dichlor-azoxybenzol manufacturers Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY. 4-p-tert.-Butyl-diphenylmethylen-piperidin suppliers providing support for flexible, cross-sector training programmes to encourage more movement and collaboration between academia, industry and the charity sector 1-methyl-4-oct-1-ynylbenzene vendor & factory These have since been joined by many other types of enzyme, including transaminases, oxidases, nitrilases, aldolases, and ammonia lyases, all of which perform distinct functions.,In the Phase III VICTORIA study, Verquvo met the primary efficacy objective based on a time-to-event analysis.